Utang jangka cendhak marang modal Cellectis Biotherapeutics (CLLS)

The linear price action for Cellectis S.A. (CLLS) on the GURU.Markets platform chart is 0.33. The business relies on external CDMO contractors for gene editing, mitigating risks by expanding production capacities. Cellectis S.A. (CLLS) is implementing advanced methods for creating universal cell therapies to make treatment accessible to the masses. The scalability of factory-scale donor product output significantly increases the operational efficiency of this biotech.

Defensive portfolio screening requires strict control over the liability structure to minimize credit risks. This indicator measures the share of short-term borrowings in total capital, allowing for an assessment of the company's dependence on immediate refinancing. For Cellectis S.A. (CLLS), this balance is critical, as the cost of patents for allogeneic CAR-T cells requires stable funding without the pressure of urgent debts. The dynamics of the ratio between current loans and capital reflect the actual trajectory of the business's financial stability.